FDA grants breakthrough designation to Glytec’s Glucommander Pediatrics

The FDA granted breakthrough device designation to Glytec's Glucommander Pediatrics, an insulin dosing recommendation algorithm intended for hospitalized newborns and infants under two years old. Breakthrough designation accelerates review pathways for devices addressing unmet clinical needs.